Anna Shi, MD
Glaucoma Specialist · Monterey, CANPI 1194093971
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Glaukos Corporation at 53.5% of the total. 2025 is the largest year on record at $13,806, more than ten times the $567 reported in 2019.
Across 306 payments — averaging $75.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$12K
- Rxsight Inc$3K
- Sight Sciences, Inc.$2K
- Alcon$1K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$631
- plus $2K from 17 others
What the payments were for
- Consulting fees$12,12652%
- Travel & lodging$4022%
- Food & beverage$10,52346%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 30 | $12,374 |
| Rxsight Inc | 6 | $3,095 |
| Sight Sciences, Inc. | 36 | $2,219 |
| Alcon | 21 | $1,279 |
| AbbVie(2 entities) | 43 | $1,207 |
| Sun Pharmaceutical Industries Inc. | 22 | $631 |
| Aerie Pharmaceuticals, Inc. | 18 | $450 |
| Biotissue Holdings Inc. | 15 | $333 |
| Tarsus Pharmaceuticals, Inc. | 55 | $333 |
| Bausch & Lomb Americas Inc. | 6 | $212 |
| Eyevance Pharmaceuticals LLC | 23 | $178 |
| Astellas Pharma US Inc | 1 | $160 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $116 |
| Novartis | 5 | $97 |
| Oyster Point Pharma, Inc. | 3 | $82 |
| Amgen(2 entities) | 4 | $81 |
| Kala Pharmaceuticals, Inc. | 3 | $65 |
| Thea Pharma Inc. | 3 | $63 |
| Beaver-visitec International, Inc. | 2 | $44 |
| Dompe US, Inc. | 2 | $38 |
| Merz North America, Inc. | 1 | $22 |
| Quidel Corporation | 1 | $17 |
| Iridex Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$9,935
- RXSIGHT CONTACT LENS$3,000
- RXSIGHT INJECTOR CARTRIDGE$3,000
- RXSIGHT INJECTOR HANDPIECE$3,000
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,000
- LIGHT ADJUSTABLE LENS (LAL)$3,000
- OMNI(R) SURGICAL SYSTEM (US)$1,257
- iDoseTR$805
- Hydrus Microstent$600
- iDose$355
- iStent Infinite$312
- CEQUA$211
- GTS100-Glaukos iStent Trabecular Micro-Bypass Stent System$172
- iStent$134
- iStent inject W$134
- XEN$124
- iStent Trabecular Micro-Bypass Stent System$123
- iStent inject Trabecular Micro-Bypass Stent System$123
- Rocklatan$122
- Rhopressa$122
How this compares
$23,113 in reported general payments places this provider in the 75th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 137 | $83,164 |
| XdemvyLotilaner | 31 | $56,666 |
| RestasisCyclosporine | 48 | $51,788 |
| VyzultaLatanoprostene Bunod | 81 | $45,704 |
| Cyclosporine | 103 | $41,418 |
| XiidraLifitegrast | 31 | $38,294 |
| RhopressaNetarsudil Mesylate | 71 | $37,301 |
| CequaCyclosporine | 28 | $35,059 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 92 | $30,248 |
| LumiganBimatoprost | 41 | $24,657 |
| Prednisolone Acetate | 321 | $14,766 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $9,855 |
| Brimonidine Tartrate | 237 | $8,740 |
| Latanoprost | 793 | $8,735 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 35 | $8,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $450 | $120,465208 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $212 | $92,347123 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,207 | $86,300115 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $333 | $56,66631 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $631 | $35,05928 claims |
| AlconSimbrinza | $1,279 | $30,24892 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Monterey
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.